Pre-vaccination type-specific HPV prevalence in confirmed cervical high grade lesions in the Māori and non-Māori populations in New Zealand
| Autor: | Hazel Lewis, Karen Canfell, Harold Neal, Leonardo Simonella, Yoon-Jung Kang, Megan Smith, Collette Bromhead |
|---|---|
| Jazyk: | angličtina |
| Předmět: |
Prevention - Vaccines
Adult medicine.medical_specialty Native Hawaiian or Other Pacific Islander Ethnic group Uterine Cervical Neoplasms Cervical intraepithelial neoplasia Indigenous populations White People Young Adult Internal medicine medicine Prevalence Humans Vaccine impact Papillomavirus Vaccines Young adult Aged HPV vaccine Gynecology Cervical cancer Human papillomavirus 16 Cervical screening Human papillomavirus 18 business.industry Papillomavirus Infections Vaccination HPV infection Middle Aged medicine.disease Uterine Cervical Dysplasia female genital diseases and pregnancy complications Infectious Diseases Tropical medicine Female Squamous Intraepithelial Lesions of the Cervix business Cancer Type - Cervical Cancer New Zealand Research Article |
| Zdroj: | BMC Infectious Diseases |
| ISSN: | 1471-2334 |
| DOI: | 10.1186/s12879-015-1034-5 |
| Popis: | Background New Zealand initiated HPV vaccination in 2008, and has attained 3-dose coverage of ~50 % in 12–13 year old girls. Due to the success of program initiatives in Māori girls, higher coverage rates of ~60 % have been achieved in this group. We have previously reported a benchmark overall pre-vaccination prevalence of oncogenic HPV infection in high grade cervical lesions in New Zealand. The current extended analysis provides separate pre-vaccination benchmark prevalence for Māori and non-Māori women. Methods The National Cervical Screening Programme Register (NCSP-R) was used to identify any woman aged 20–69 years of age with an index high grade cytology report from 2009–2011. Extended recruitment was performed until 2012 in clinics with a high proportion of Māori women. Ethnicity status was based on self-reported information by participating women through phone contact supplemented by recordings on the study questionnaire (the NCSP-R was not used to extract ethnicity status). A total of 730 women consented to participate and had a valid HPV test result; 418 of these had histologically-confirmed cervical intraepithelial neoplasia (CIN) 2/3 lesions (149 Māori, 269 non-Māori). The prevalence of any cervical oncogenic HPV infection, HPV16, and HPV18 was calculated in women with CIN2/3. Results In confirmed CIN2/3, the prevalence of any oncogenic HPV, HPV16 and HPV18 was 96 % (95 % CI:91–99 %), 54 % (95 % CI:46–63 %), 11 % (95 % CI:7–18 %) in Māori and 96 % (95 % CI:93–98 %), 54 % (95 % CI:48–60 %), 11 % (95 % CI:7–15 %) in non-Māori women, respectively. Age-specific patterns of infection for HPV16/18 in confirmed CIN2/3 differed between the two groups (Pinteraction = 0.02), with a lower prevalence in younger vs. older Māori women (57 % in 20–29 years vs 75 % in 40–69 years) but a higher prevalence in younger vs. older non-Māori women (70 % in 20–29 years vs 49 % in 40–69 years); the difference in the age-specific patterns of infection for HPV16/18 was not significant either when considering confirmed CIN2 alone (p = 0.09) or CIN3 alone (p = 0.22). Conclusions The overall prevalence of vaccine-included types in CIN2/3 was similar in Māori and non-Māori women, implying that the long-term effects of vaccination will be similar in the two groups. Electronic supplementary material The online version of this article (doi:10.1186/s12879-015-1034-5) contains supplementary material, which is available to authorized users. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|